Cystic fibrosis is treatable, and treatment has improved so dramatically in recent decades that babies born with CF today are predicted to live to a median age of 65, according to 2024 data from the Cystic Fibrosis Foundation. There is no cure yet, but a combination of daily therapies, newer drugs that fix the underlying protein defect, infection management, and nutritional support can significantly slow lung damage and improve quality of life.
How CF Treatment Has Changed
For most of CF’s history, treatment was purely symptom-based: clearing mucus, fighting infections, and replacing digestive enzymes. These therapies remain essential, but the landscape shifted with the arrival of a class of drugs called CFTR modulators, which target the root cause of the disease rather than just its downstream effects. The first modulator was approved for only about 4% of people with CF. Today, roughly 90% of people with CF carry a mutation eligible for modulator therapy.
That said, the remaining 10% still rely entirely on symptom-based treatments. And even for those on modulators, daily airway clearance and nutritional support remain part of the routine. CF treatment is not a single pill; it’s a layered system of therapies that work together.
CFTR Modulators: Treating the Root Cause
In CF, a faulty gene produces a defective version of a protein called CFTR, which normally moves salt and water across cell surfaces. When CFTR doesn’t work, mucus throughout the body becomes thick and sticky, clogging the lungs and pancreas. CFTR modulators are drugs designed to either fix the shape of the defective protein so it reaches the cell surface (correctors) or help the protein open and close properly once it gets there (potentiators).
The most widely used modulator is Trikafta, a triple-combination therapy that pairs two correctors with one potentiator. By using two correctors with different mechanisms, Trikafta repairs multiple defects in the most common CF mutation (called F508del) more effectively than earlier two-drug combinations could. Clinical trials showed meaningful improvements in lung function, measured by how much air a person can forcefully exhale in one second. Patients also experience fewer lung flare-ups, gain weight, and report breathing more easily in daily life.
Earlier modulators like Kalydeco (the first approved potentiator) work well for people with specific gating mutations, where the protein reaches the cell surface but doesn’t open properly. Kalydeco essentially increases how often the channel opens, allowing salt and water to flow more normally. Each modulator targets different mutation types, so genetic testing determines which therapy, if any, a person is eligible for.
Daily Airway Clearance
Thick mucus trapped in the lungs is the central problem in CF, creating a breeding ground for bacteria and driving progressive lung damage. Airway clearance techniques are performed daily, often twice a day, to loosen and move that mucus out. The specific method varies by age, preference, and lifestyle.
Traditional chest physiotherapy involves someone clapping on the chest and back in specific positions to shake mucus loose. Many people now use devices that let them do this independently. Oscillating devices like the Flutter or Acapella create vibrations inside the airways when you breathe through them. Vest systems like The Vest or SmartVest use rapid external chest compressions to achieve a similar effect. Breathing techniques such as the active cycle of breathing or autogenic drainage use controlled inhaling and exhaling patterns to shift mucus from smaller airways into larger ones where it can be coughed out. Exercise also helps by changing airflow patterns and improving overall lung strength.
Before or during these sessions, inhaled medications help thin the mucus. Hypertonic saline (a concentrated saltwater solution) draws water into the airways, hydrating the mucus so it’s easier to move. Another inhaled therapy called dornase alfa breaks down DNA released by dead white blood cells in the mucus, reducing its stickiness. These treatments are typically nebulized, meaning they’re inhaled as a fine mist.
Fighting Lung Infections
The thick mucus environment in CF lungs makes chronic bacterial infections nearly inevitable. Pseudomonas aeruginosa is the most significant of these bacteria, and early, aggressive treatment to eradicate it can delay chronic colonization. Inhaled antibiotics are a cornerstone of this effort, delivered directly to the lungs to achieve high local concentrations while minimizing side effects elsewhere in the body. Inhaled tobramycin is one of the most studied options, and trials show it significantly improves the odds of clearing Pseudomonas compared to no treatment.
When infections flare up, causing increased coughing, reduced lung function, or fever, oral or intravenous antibiotics may be needed. These flare-ups, called pulmonary exacerbations, often require two or more weeks of intensive antibiotic treatment. Some people with advanced disease cycle through these exacerbations multiple times per year, and frequent flare-ups are one of the markers that signal worsening disease.
Nutritional and Digestive Support
CF doesn’t just affect the lungs. In most people with the condition, thick secretions block the ducts of the pancreas, preventing digestive enzymes from reaching the intestines. Without these enzymes, the body can’t properly absorb fats and fat-soluble vitamins from food. This leads to poor weight gain, nutritional deficiencies, and digestive symptoms like greasy stools, bloating, and abdominal pain.
The fix is pancreatic enzyme replacement, taken as capsules with every meal and snack. The capsules contain enzymes coated in a special shell that protects them from stomach acid, releasing them only when they reach the intestines. Dosing is based on how much fat is in the meal. For older children and adults, the typical range is 500 to 4,000 enzyme units per gram of fat eaten, adjusted based on symptoms and growth. If a capsule is hard to swallow, it can be opened and the contents mixed into a small amount of applesauce or similar soft food, but the tiny beads inside shouldn’t be crushed.
People with CF are encouraged to eat a high-calorie, high-fat diet. This is the opposite of typical dietary advice, but it’s essential because even with enzyme replacement, fat absorption is imperfect. High-fat diets have been shown to promote better growth and lung function compared to low-fat diets. Fat-soluble vitamins (A, D, E, and K) are supplemented as well, since absorption of these is particularly affected.
Lung Transplant as a Late-Stage Option
For people whose lung function declines severely despite all available therapies, lung transplantation becomes a consideration. The Cystic Fibrosis Foundation recommends that care teams begin discussing transplant when lung function drops below 50% of predicted values. Formal referral to a transplant center is recommended when lung function falls below 30%, or below 40% with additional warning signs like needing supplemental oxygen, being unable to walk 400 meters in six minutes, losing significant weight, or experiencing more than two serious infections per year requiring intravenous antibiotics.
Transplant is not a cure for CF. The new lungs won’t have the CF defect, but the disease continues to affect the sinuses, pancreas, and other organs. Recovery is significant, and lifelong anti-rejection medications are required. Still, for people with end-stage lung disease, transplant can extend life and dramatically improve daily functioning.
Life Expectancy Today
The predicted survival for people with CF has climbed steadily. Based on the Cystic Fibrosis Foundation’s 2024 Registry data, a baby born with CF between 2020 and 2024 has a predicted median survival of 65 years, assuming current treatments remain available throughout their lifetime. That number reflects the impact of CFTR modulators and modern care protocols.
The picture is more sobering for people already living with advanced disease. Among deaths reported in the Registry in 2024, half occurred before age 38.8. This gap between predicted survival for newborns and actual age of death for current patients highlights the reality that many adults with CF grew up before modulators existed, and their lungs sustained irreversible damage during those years. For the generation now growing up with access to these therapies from early childhood, the trajectory looks substantially different.